Details for Patent: 7,973,038

Which drugs does patent 7,973,038 protect, and when does it expire?

Patent 7,973,038 protects ORKAMBI and is included in two NDAs.

This patent has ninety patent family members in twenty-five countries.

Summary for Patent: 7,973,038

Title:	Modulators of ATP-binding cassette transporters
Abstract:	Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s):	Hadida Ruah; Sara S. (LaJolla, CA), Hamilton; Matthew (New Jersey, CA), Miller; Mark T. (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian Richard (Oceanside, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	12/768,894
Patent Claim Types: see list of patent claims	Use;

United States Patent 7,973,038: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 7,973,038, titled "Modulators of ATP-binding cassette transporters," is a significant patent in the field of pharmaceuticals, particularly in the area of transporter modulation. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background

ATP-binding cassette (ABC) transporters are a family of proteins that play crucial roles in various biological processes, including the transport of drugs, ions, and other molecules across cell membranes. The modulation of these transporters is of great interest for treating diseases such as cystic fibrosis, emphysema, and chronic obstructive pulmonary disease (COPD)[4].

Scope of the Patent

The patent US7973038B2 covers compounds and their pharmaceutically acceptable compositions that are useful as modulators of ABC transporters. These compounds are designed to interact with specific ABC transporters, thereby modulating their activity. The scope includes a wide range of chemical structures, such as heteroaryl, aliphatic, and cycloalkyl groups, which are optionally substituted to enhance their therapeutic efficacy[4].

Claims

The patent includes several claims that define the scope of the invention:

Independent Claims

• Claim 1 describes the general structure of the compounds, including the core heteroaryl ring and various substituents.
• Claim 2 specifies the pharmaceutical compositions containing these compounds.
• Claim 3 outlines the methods of treating diseases associated with ABC transporters using these compounds[4].

Dependent Claims

• These claims further narrow down the scope by specifying particular substituents, such as hydroxy, carboxy, nitro, and trifluoromethoxy groups, and their positions on the core structure.
• Other dependent claims cover specific salts and solvates of the compounds, as well as their use in treating specific diseases like cystic fibrosis and COPD[4].

Chemical Structure and Substituents

The patent describes a variety of chemical groups that can be part of the modulator compounds. These include:

• Heteroaryl groups such as pyridyl and naphthyl.
• Aliphatic groups like ethyl, cyclopropyl, and cyclopentyl.
• Functional groups such as hydroxy, carboxy, nitro, and trifluoromethoxy.
• The presence of these groups and their specific arrangements are crucial for the biological activity of the compounds[4].

Therapeutic Applications

The compounds and compositions described in the patent are intended for the treatment of various diseases associated with ABC transporters. Key therapeutic applications include:

• Cystic Fibrosis: Modulation of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
• Emphysema and COPD: Treatment of respiratory diseases by modulating ABC transporters involved in lung function.
• Other diseases where ABC transporters play a significant role[4].

Patent Landscape

Related Patents

The patent US7973038B2 is part of a larger patent family that includes other related patents and applications. For example, the priority date and referenced patents indicate a series of inventions aimed at modulating ABC transporters for therapeutic purposes[2][4].

International Patent Offices

To understand the global patent landscape, it is essential to search international patent databases. Resources like the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) provide access to international patent applications and grants. This helps in identifying similar inventions and potential competitors[1].

Prior Art and Citation Data

The Common Citation Document (CCD) application is useful for consolidating prior art cited by multiple patent offices for the same invention. This tool helps in understanding the prior art landscape and the novelty of the invention described in US7973038B2[1].

Search and Analysis Tools

For a comprehensive analysis, several tools and resources are available:

• Patent Public Search: A web-based tool provided by the USPTO for searching prior art and related patents.
• Global Dossier: A service that provides access to the file histories of related applications from participating IP offices.
• Patent Examination Data System (PEDS): Allows public users to search, view, and download bibliographic data for patent applications[1].

Economic and Research Implications

The Patent Claims Research Dataset provided by the USPTO can offer insights into the scope and claims of patents like US7973038B2. This dataset includes detailed information on claims from US patents and applications, which can be used to analyze trends and measurements of patent scope[3].

Key Takeaways

• Scope and Claims: The patent covers a broad range of compounds and compositions useful for modulating ABC transporters, with specific claims defining the structure and therapeutic applications.
• Therapeutic Applications: The compounds are intended for treating diseases such as cystic fibrosis, emphysema, and COPD.
• Patent Landscape: The patent is part of a larger family of related inventions, and international patent databases should be consulted to understand the global landscape.
• Tools and Resources: Various tools like Patent Public Search, Global Dossier, and PEDS are available for comprehensive analysis.

FAQs

Q: What is the main focus of United States Patent 7,973,038?

A: The main focus is on compounds and their compositions that modulate ATP-binding cassette (ABC) transporters for therapeutic purposes.

Q: Which diseases are targeted by the compounds described in the patent?

A: The compounds are intended for treating diseases such as cystic fibrosis, emphysema, and chronic obstructive pulmonary disease (COPD).

Q: How can one search for related patents internationally?

A: One can use resources like the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) to search international patent databases.

Q: What tools are available for analyzing the patent landscape?

A: Tools such as Patent Public Search, Global Dossier, and the Patent Examination Data System (PEDS) are available for comprehensive analysis.

Q: Where can one find detailed information on claims from US patents?

A: The Patent Claims Research Dataset provided by the USPTO includes detailed information on claims from US patents and applications.

Sources

1. USPTO - Search for patents: https://www.uspto.gov/patents/search
2. Unified Patents Portal - WO-2001054690-A1: https://portal.unifiedpatents.com/patents/patent/WO-2001054690-A1
3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
4. Google Patents - US7973038B2: https://patents.google.com/patent/US7973038B2/en

Drugs Protected by US Patent 7,973,038

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No						TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No						TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-002	Aug 7, 2018		RX	Yes	Yes						TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-002	Sep 28, 2016		RX	Yes	No						METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-001	Jul 2, 2015		RX	Yes	Yes						METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

International Family Members for US Patent 7,973,038

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2404919		PA2016015	Lithuania
European Patent Office	2404919		93073	Luxembourg
European Patent Office	2404919		CA 2016 00019	Denmark
European Patent Office	2395002		300812	Netherlands
European Patent Office	2404919		16C0020	France
European Patent Office	2404919		C20160015 00195	Estonia